Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
复制标题
DOI：
10.1086/368083
复制
发表时间：
2003-03-15
影响因子：
11.8
通讯作者：
Condreay, L
中科院分区：
文献类型：
--
作者：
Lai, CL;Dienstag, J;Condreay, L
一些接受拉米夫定治疗的慢性乙型肝炎患者中出现乙型肝炎病毒 (HBV) 的 YMDD 变种。在 4 项为期 1 年的对照研究中，对 794 名患者进行了 YMDD 变异检查。在治疗长达 4 年的患者子集中检查了 YMDD 变异的长期影响。通过聚合酶链式反应 (PCR) 和限制性片段长度多态性测定检测 YMDD 变异。 1 年后，335 名患者中有 81 名 (24%) 检测到 YMDD 变异。在这些患者中，1 年时的中位血清 HBV DNA 浓度为
YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4 years. YMDD variants were detected by polymerase chain reaction (PCR) and restriction fragment-length polymorphism assays. After 1 year, YMDD variants were detected in 81 (24%) of 335 patients. In these patients, the median serum HBV DNA concentration at 1 year was